Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 23Unspecified Adult Solid Tumor, Protocol Specific 14Urinary Bladder Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 9Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms 6Adenocarcinoma of Lung 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Lymphoma, Follicular 5Carcinoma, Ovarian Epithelial 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Colonic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Neoplasms 3

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Complete Response × Gemcitabine × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡